A Phase IIa Study to Evaluate the Safety, Tolerability and Acceptability of Long Acting Injections of the HIV Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

Trial Profile

A Phase IIa Study to Evaluate the Safety, Tolerability and Acceptability of Long Acting Injections of the HIV Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

Completed
Phase of Trial: Phase II

Latest Information Update: 11 May 2016

At a glance

  • Drugs Cabotegravir (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Acronyms ECLAIR
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 11 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 25 Feb 2016 Results presented at the 23rd Conference on Retroviruses and Opportunistic Infections
    • 25 Feb 2016 Results (subgroup analysis, n = 28) assessing pain and anxiety experienced around cabotegravir long-acting injection in MSM or male-to-female transgender women presented at the 23rd Conference on Retroviruses and Opportunistic Infections.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top